ALK may be therefore particularly suited for co-targeting with SHP2 in the treatment of NSCLC, as it is not widely expressed after embryonic development is complete29 (such that the systemic toxicity of ALK inhibitors is low). The gene discussed is ALK; the disease is non-small cell lung carcinoma.